By targeting EGFR with the antibody cetuximab, administered to treat metastatic K-RAS wild-type CRC patients (58), our data indicate that exhausted NK cells could be activated in presence of IL-2 or IL-15. The gene discussed is KRAS; the disease is colorectal carcinoma.